Kura Oncology Earnings Estimate
| KURA Stock | USD 8.31 0.29 3.62% |
Kura Oncology Earnings Estimation Breakdown
The calculation of Kura Oncology's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Kura Oncology is estimated to be -0.8867 with the future projection ranging from a low of -0.98 to a high of -0.62. Please be aware that this consensus of annual earnings estimates for Kura Oncology is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.98 Lowest | Expected EPS | -0.62 Highest |
Kura Oncology Earnings Projection Consensus
Suppose the current estimates of Kura Oncology's value are higher than the current market price of the Kura Oncology stock. In this case, investors may conclude that Kura Oncology is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Kura Oncology's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 15 | 76.91% | 0.0 | -0.8867 | -2.48 |
Kura Oncology Earnings per Share Projection vs Actual
Actual Earning per Share of Kura Oncology refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Kura Oncology predict the company's earnings will be in the future. The higher the earnings per share of Kura Oncology, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Kura Oncology Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Kura Oncology, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Kura Oncology should always be considered in relation to other companies to make a more educated investment decision.Kura Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Kura Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-04 | 2025-09-30 | -0.75 | -0.85 | -0.1 | 13 | ||
2025-08-07 | 2025-06-30 | -0.41 | -0.75 | -0.34 | 82 | ||
2025-06-05 | 2025-03-31 | -0.6001 | -0.66 | -0.0599 | 9 | ||
2025-02-25 | 2024-12-31 | -0.6375 | -0.22 | 0.4175 | 65 | ||
2024-11-07 | 2024-09-30 | -0.63 | -0.63 | 0.0 | 0 | ||
2024-08-08 | 2024-06-30 | -0.63 | -0.59 | 0.04 | 6 | ||
2024-05-02 | 2024-03-31 | -0.55 | -0.59 | -0.04 | 7 | ||
2024-02-27 | 2023-12-31 | -0.55 | -0.55 | 0.0 | 0 | ||
2023-11-02 | 2023-09-30 | -0.55 | -0.5 | 0.05 | 9 | ||
2023-08-03 | 2023-06-30 | -0.55 | -0.53 | 0.02 | 3 | ||
2023-05-10 | 2023-03-31 | -0.54 | -0.5 | 0.04 | 7 | ||
2023-02-23 | 2022-12-31 | -0.57 | -0.49 | 0.08 | 14 | ||
2022-11-03 | 2022-09-30 | -0.56 | -0.53 | 0.03 | 5 | ||
2022-08-03 | 2022-06-30 | -0.52 | -0.52 | 0.0 | 0 | ||
2022-05-04 | 2022-03-31 | -0.52 | -0.49 | 0.03 | 5 | ||
2022-02-24 | 2021-12-31 | -0.53 | -0.49 | 0.04 | 7 | ||
2021-11-04 | 2021-09-30 | -0.54 | -0.5 | 0.04 | 7 | ||
2021-08-05 | 2021-06-30 | -0.49 | -0.51 | -0.02 | 4 | ||
2021-05-06 | 2021-03-31 | -0.42 | -0.46 | -0.04 | 9 | ||
2021-02-24 | 2020-12-31 | -0.45 | -0.45 | 0.0 | 0 | ||
2020-11-05 | 2020-09-30 | -0.4 | -0.42 | -0.02 | 5 | ||
2020-08-06 | 2020-06-30 | -0.42 | -0.4 | 0.02 | 4 | ||
2020-05-04 | 2020-03-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2020-02-25 | 2019-12-31 | -0.41 | -0.39 | 0.02 | 4 | ||
2019-11-05 | 2019-09-30 | -0.39 | -0.36 | 0.03 | 7 | ||
2019-08-01 | 2019-06-30 | -0.41 | -0.38 | 0.03 | 7 | ||
2019-05-07 | 2019-03-31 | -0.44 | -0.37 | 0.07 | 15 | ||
2019-03-05 | 2018-12-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2018-11-05 | 2018-09-30 | -0.43 | -0.4 | 0.03 | 6 | ||
2018-08-06 | 2018-06-30 | -0.45 | -0.45 | 0.0 | 0 | ||
2018-05-08 | 2018-03-31 | -0.35 | -0.46 | -0.11 | 31 | ||
2018-03-12 | 2017-12-31 | -0.36 | -0.37 | -0.01 | 2 | ||
2017-11-07 | 2017-09-30 | -0.37 | -0.38 | -0.01 | 2 | ||
2017-08-07 | 2017-06-30 | -0.42 | -0.4 | 0.02 | 4 | ||
2017-05-15 | 2017-03-31 | -0.44 | -0.39 | 0.05 | 11 | ||
2017-03-14 | 2016-12-31 | -0.4 | -0.38 | 0.02 | 5 | ||
2016-11-07 | 2016-09-30 | -0.4 | -0.37 | 0.03 | 7 | ||
2016-08-10 | 2016-06-30 | -0.38 | -0.36 | 0.02 | 5 | ||
2016-05-11 | 2016-03-31 | -0.37 | -0.36 | 0.01 | 2 | ||
2016-03-17 | 2015-12-31 | -0.48 | -0.42 | 0.06 | 12 | ||
2015-11-13 | 2015-09-30 | -0.42 | -0.57 | -0.15 | 35 |
About Kura Oncology Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Kura Oncology earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Kura Oncology estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Kura Oncology fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -805.9 M | -765.6 M | |
| Retained Earnings Total Equity | -511.9 M | -486.3 M | |
| Earnings Yield | (0.27) | (0.25) | |
| Price Earnings Ratio | (3.88) | (4.08) | |
| Price Earnings To Growth Ratio | 1.35 | 1.41 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. Expected growth trajectory for Kura significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kura Oncology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Kura Oncology requires distinguishing between market price and book value, where the latter reflects Kura's accounting equity. The concept of intrinsic value - what Kura Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kura Oncology's price substantially above or below its fundamental value.
Understanding that Kura Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kura Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kura Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.